Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Mar 27, 2026; 18(3): 115383
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.115383
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.115383
Table 1 Comparison of clinical data among the three groups, mean ± SD
| Groups | n | Sex | Age (years) | |
| Male | Female | |||
| Indomethacin group | 129 | 68 | 61 | 63.8 ± 13.5 |
| Stent group | 128 | 62 | 67 | 61.4 ± 12.9 |
| Combined group | 129 | 70 | 59 | 61.7 ± 12.7 |
| χ2/F value | - | 1.60 | 0.30 | |
| P value | - | 0.450 | 0.74 | |
Table 2 Comparison of related inflammatory factors before and after surgery among the three groups, mean ± SD
| Groups | IL-6 (pg/mL) | IL-10 (pg/mL) | CRP (mg/L) | |||
| Before surgery | 24 hours after surgery | Before surgery | 24 hours after surgery | Before surgery | 24 hours after surgery | |
| Indomethacin group | 12.3 ± 1.2 | 58.7 ± 5.3 | 8.5 ± 0.9 | 32.1 ± 3.2 | 5.2 ± 0.6 | 28.4 ± 2.8 |
| Stent group | 11.8 ± 1.1 | 62.4 ± 5.8 | 8.2 ± 0.8 | 35.6 ± 3.5 | 5.0 ± 0.5 | 31.7 ± 3.1 |
| Combined group | 12.1 ± 1.3 | 42.6 ± 4.1 | 8.4 ± 0.7 | 24.3 ± 2.4 | 5.1 ± 0.6 | 19.8 ± 1.9 |
| F-score | 0.82 | 35.67 | 0.91 | 28.43 | 0.75 | 30.15 |
| P value | 0.35 | 0.008 | 0.28 | 0.013 | 0.41 | 0.021 |
Table 3 Comparison of immune function before and after surgery among the three groups, mean ± SD
| Groups | CD4+ (%) | CD8+ (%) | CD4+/CD8+ (%) | |||
| Before surgery | 24 hours after surgery | Before surgery | 24 hours after surgery | Before surgery | 24 hours after surgery | |
| Indomethacin group | 42.3 ± 3.1 | 35.6 ± 2.8 | 26.5 ± 2.1 | 31.2 ± 2.5 | 1.60 ± 0.12 | 1.14 ± 0.09 |
| Stent group | 41.8 ± 3.0 | 36.2 ± 2.9 | 26.8 ± 2.0 | 30.8 ± 2.4 | 1.56 ± 0.11 | 1.18 ± 0.10 |
| Combined group | 42.1 ± 3.2 | 39.5 ± 3.0 | 26.3 ± 2.2 | 28.1 ± 2.2 | 1.60 ± 0.13 | 1.41 ± 0.11 |
| F-score | 0.85 | 18.72 | 0.78 | 15.43 | 0.82 | 20.15 |
| P value | 0.47 | 0.007 | 0.52 | 0.012 | 0.43 | 0.005 |
Table 4 Comparison of postoperative post-endoscopic retrograde cholangiopancreatography pancreatitis and severe post-endoscopic retrograde cholangiopancreatography pancreatitis among the three groups, n (%)
| Groups | PEP | Severe PEP |
| Indomethacin group | 28 (21.7) | 1 (0.01) |
| Stent group | 13 (10.2) | 1 (0.01) |
| Combined group | 8 (6.2) | 0 |
| χ2 | 14.63 | - |
| P value | 0.0007 | 0.369 |
Table 5 Comparison of postoperative pain relief time and length of hospital stay among the three groups, mean ± SD
| Groups | Pain relief time | Length of hospital stay |
| Indomethacin group | 18.96 ± 2.87 | 10.58 ± 1.51 |
| Stent group | 16.34 ± 2.15 | 9.62 ± 1.48 |
| Combined group | 14.28 ± 1.89 | 8.21 ± 1.32 |
| F-score | 12.45 | 15.82 |
| P value | 0.0003 | 0.0001 |
- Citation: Xu K, Zhou DH, Liu JS, Feng J. Impact of indomethacin combined with pancreatic duct stent placement on high-risk populations of pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastrointest Surg 2026; 18(3): 115383
- URL: https://www.wjgnet.com/1948-9366/full/v18/i3/115383.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i3.115383
